Fig. 1: Survival based on bridging therapy strategy. | Blood Cancer Journal

Fig. 1: Survival based on bridging therapy strategy.

From: Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

Fig. 1

Kaplan-Meier plots estimates of PFS A and OS B in RRMM patients treated with idecabtagene vicleucel, between those with and without bridging therapy. Kaplan-Meier estimates of PFS C and OS D categorized by bridging therapy type (no-BT, Selinexor, alkylator, PI combos, IMiD±mAb combos). Kaplan-Meier estimates of PFS E and OS F categorized based on cyclophosphamide dosing and exposure as bridging therapy.

Back to article page